Medtronic plc (MDT) |
| 88.28 0.28 (0.32%) 04-14 10:48 |
| Open: | 88 |
| High: | 88.515 |
| Low: | 87 |
| Volume: | 1,239,899 |
| Market Cap: | 113,341(M) |
| PE Ratio: | 24.66 |
| Exchange: | New York Stock Exchange |
| Industry: | Medical - Devices |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 91.41 |
| Resistance 1: | 88.94 |
| Pivot price: | 87.13 |
| Support 1: | 84.93 |
| Support 2: | 70.67 |
| 52w High: | 106.33 |
| 52w Low: | 79.93 |
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.
| EPS | 3.580 |
| Book Value | 38.170 |
| PEG Ratio | 0.00 |
| Gross Profit | 18.063 |
| Profit Margin (%) | 13.00 |
| Operating Margin (%) | 20.01 |
| Return on Assets (ttm) | 4.6 |
| Return on Equity (ttm) | 9.4 |
Tue, 14 Apr 2026
Jim Cramer on Medtronic (MDT): "I think that everything they’ve been doing lately is right" - MSN
Mon, 13 Apr 2026
Medtronic (MDT) Valuation Check After New GE HealthCare Surgical Imaging Integration - Sahm
Sun, 12 Apr 2026
Medtronic plc (MDT): Innovation Pipeline and Structural Changes Support the Bull Case - Insider Monkey
Sun, 12 Apr 2026
Sumitomo Mitsui Trust Group Inc. Sells 29,238 Shares of Medtronic PLC $MDT - MarketBeat
Sun, 12 Apr 2026
Medtronic PLC $MDT is Cambiar Investors LLC's 7th Largest Position - MarketBeat
Sun, 12 Apr 2026
Beacon Harbor Wealth Advisors Inc. Takes Position in Medtronic PLC $MDT - MarketBeat
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |